Prevalence of hepatitis C infection, screening and associated factors among men who have sex with men attending gay venues: a cross-sectional survey (PREVAGAY), France, 2015.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
11 Apr 2019
Historique:
received: 15 03 2019
accepted: 29 03 2019
entrez: 12 4 2019
pubmed: 12 4 2019
medline: 6 7 2019
Statut: epublish

Résumé

Over the last 20 years, Hepatitis C virus (HCV) infection prevalence has dramatically increased among HIV-infected men who have sex with men (MSM) in many countries worldwide. It is suspected that this increase is primarily driven by sexual behaviours linked to blood exposure. Monitoring these behaviours is crucial to understand the drivers of the epidemic. This study assessed the prevalence of chronic HCV infection among MSM attending gay venues and associated chronic HCV risk factors. HCV screening and associated factors were described. The cross-sectional survey PREVAGAY, based on time-location sampling, was conducted in 2015 among MSM attending gay venues in 5 French metropolitan cities. A self-administered questionnaire was completed and capillary whole blood on dried blood spots (DBS) collected. Possible factors associated with chronic HCV prevalence and with HCV screening in the previous year were investigated using Poisson regression. Chronic HCV infection prevalence from DBS analysis was 0.7% [IC95%: 0.3-1.5] in the study's 2645 participants and was 3.0% [1.5-5.8] in HIV-positive MSM. It was significantly higher in those who reported the following: (lifetime) slamming (with or without the sharing of injection equipment); (during the previous year) fisting and chemsex, unprotected anal intercourse with casual partners, using gay websites and/or of mobile-based GPS applications, and having more than 10 sexual partners. Only 41.3% [38.2-44.5] of the participants reported HCV screening during the previous year. Screening was significantly more frequent in MSM under 30 years of age, those who were HIV-positive, those vaccinated against hepatitis B and meningococcus C, and those who reported the following (during the previous year): more than 10 sexual partners, at least one sexually transmitted infection and fisting. Chronic HCV infection prevalence in MSM attending gay venues was significantly higher in HIV-positive MSM and in those with risky sexual behaviours. Reflecting current screening recommendations for specific populations, previous HCV screening was more frequent in HIV-positive individuals and those with risky sexual behaviours. Nevertheless, HCV screening coverage needs to be improved in these populations. Comprehensive medical management, which combines screening and linkage to care with prevention strategies, is essential to control HCV among MSM.

Sections du résumé

BACKGROUND BACKGROUND
Over the last 20 years, Hepatitis C virus (HCV) infection prevalence has dramatically increased among HIV-infected men who have sex with men (MSM) in many countries worldwide. It is suspected that this increase is primarily driven by sexual behaviours linked to blood exposure. Monitoring these behaviours is crucial to understand the drivers of the epidemic. This study assessed the prevalence of chronic HCV infection among MSM attending gay venues and associated chronic HCV risk factors. HCV screening and associated factors were described.
METHODS METHODS
The cross-sectional survey PREVAGAY, based on time-location sampling, was conducted in 2015 among MSM attending gay venues in 5 French metropolitan cities. A self-administered questionnaire was completed and capillary whole blood on dried blood spots (DBS) collected. Possible factors associated with chronic HCV prevalence and with HCV screening in the previous year were investigated using Poisson regression.
RESULTS RESULTS
Chronic HCV infection prevalence from DBS analysis was 0.7% [IC95%: 0.3-1.5] in the study's 2645 participants and was 3.0% [1.5-5.8] in HIV-positive MSM. It was significantly higher in those who reported the following: (lifetime) slamming (with or without the sharing of injection equipment); (during the previous year) fisting and chemsex, unprotected anal intercourse with casual partners, using gay websites and/or of mobile-based GPS applications, and having more than 10 sexual partners. Only 41.3% [38.2-44.5] of the participants reported HCV screening during the previous year. Screening was significantly more frequent in MSM under 30 years of age, those who were HIV-positive, those vaccinated against hepatitis B and meningococcus C, and those who reported the following (during the previous year): more than 10 sexual partners, at least one sexually transmitted infection and fisting.
CONCLUSION CONCLUSIONS
Chronic HCV infection prevalence in MSM attending gay venues was significantly higher in HIV-positive MSM and in those with risky sexual behaviours. Reflecting current screening recommendations for specific populations, previous HCV screening was more frequent in HIV-positive individuals and those with risky sexual behaviours. Nevertheless, HCV screening coverage needs to be improved in these populations. Comprehensive medical management, which combines screening and linkage to care with prevention strategies, is essential to control HCV among MSM.

Identifiants

pubmed: 30971207
doi: 10.1186/s12879-019-3945-z
pii: 10.1186/s12879-019-3945-z
pmc: PMC6458747
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

315

Subventions

Organisme : Agence Nationale de Recherches sur le Sida et les Hépatites Virales
ID : 15249

Investigateurs

Annie Velter (A)
Antonio Alexandre (A)
Francis Barin (F)
Stéphane Chevaliez (S)
David Friboulet (D)
Marie Jauffret-Roustide (M)
Florence Lot (F)
Nathalie Lydié (N)
Gilles Peytavin (G)
Olivier Robineau (O)
Leila Saboni (L)
Claire Sauvage (C)
Cécile Sommen (C)

Références

JAMA. 2000 Jul 26;284(4):450-6
pubmed: 10904508
Sex Transm Dis. 2001 Sep;28(9):515-20
pubmed: 11518868
Sex Transm Infect. 2006 Aug;82(4):298-300
pubmed: 16877578
Gastroenterology. 2006 Oct;131(4):1040-8
pubmed: 17030174
Public Health Rep. 2007;122 Suppl 1:39-47
pubmed: 17354526
AIDS. 2008 Oct 1;22(15):1979-91
pubmed: 18784461
Gastroenterology. 2009 May;136(5):1609-17
pubmed: 19422083
J Med Virol. 2010 Apr;82(4):546-55
pubmed: 20166185
AIDS. 2010 Jul 31;24(12):1799-812
pubmed: 20601854
AIDS. 2011 Feb 20;25(4):399-409
pubmed: 21139491
PLoS One. 2011;6(12):e29322
pubmed: 22216248
PLoS One. 2012;7(6):e39872
pubmed: 22768150
Sex Transm Infect. 2012 Nov;88(7):558-64
pubmed: 22859499
AIDS Behav. 2013 May;17(4):1266-78
pubmed: 22968398
Curr Opin Infect Dis. 2013 Feb;26(1):66-72
pubmed: 23242342
PLoS One. 2013 Apr 16;8(4):e61225
pubmed: 23613817
Sex Health. 2013 Jul;10(3):268-74
pubmed: 23639110
Am J Epidemiol. 2013 May 15;177(10):1157-64
pubmed: 23639936
BMC Public Health. 2013 Oct 18;13:968
pubmed: 24139406
J Sex Res. 2014;51(4):390-409
pubmed: 24754360
PLoS One. 2014 Nov 19;9(11):e113167
pubmed: 25409440
Biostatistics. 2015 Jul;16(3):565-79
pubmed: 25597489
Sex Transm Infect. 2015 Dec;91(8):564-8
pubmed: 26163510
AIDS. 2015 Nov;29(17):2335-45
pubmed: 26258525
J Infect Dis. 2016 Apr 1;213(7):1087-95
pubmed: 26333945
J Int AIDS Soc. 2015 Nov 11;18:20526
pubmed: 26563846
PLoS One. 2015 Dec 31;10(12):e0145953
pubmed: 26720298
Int J STD AIDS. 2017 Feb;28(2):145-159
pubmed: 26826159
Rev Epidemiol Sante Publique. 2016 Sep;64(4):301-12
pubmed: 26904917
Lancet Infect Dis. 2016 Jul;16(7):797-808
pubmed: 26922272
Open Forum Infect Dis. 2016 Mar 11;3(2):ofw057
pubmed: 27186582
Clin Microbiol Infect. 2016 Oct;22(10):846-852
pubmed: 27297320
Sex Transm Infect. 2017 Feb;93(1):52-55
pubmed: 27356041
J Hepatol. 2016 Oct;65(1 Suppl):S33-S45
pubmed: 27641987
J Hepatol. 2017 Feb;66(2):282-287
pubmed: 27650285
Clin Infect Dis. 2017 Feb 1;64(3):284-288
pubmed: 28013267
Sex Transm Infect. 2017 Sep;93(6):404-409
pubmed: 28130506
J Infect. 2017 Sep;75(3):234-241
pubmed: 28579302
BMC Infect Dis. 2017 Nov 1;17(Suppl 1):693
pubmed: 29143616
AIDS. 2018 May 15;32(8):1077-1082
pubmed: 29438195
Epidemiol Infect. 2018 May;146(7):913-919
pubmed: 29606158
Int J STD AIDS. 2018 Sep;29(10):949-967
pubmed: 29716442
Sex Transm Infect. 2018 Nov;94(7):502-507
pubmed: 29779005
J Hepatol. 2018 Oct;69(4):916-926
pubmed: 29800630
Clin Infect Dis. 2018 Oct 30;67(10):1477-1492
pubmed: 30215672
Curr Opin Infect Dis. 2019 Feb;32(1):31-37
pubmed: 30531370

Auteurs

Sophie Vaux (S)

Department of Infectious Diseases - Santé publique France, French national public health agency, 12 rue du Val d'Osne, 94415, Saint-Maurice, Cedex, France. sophie.vaux@santepubliquefrance.fr.

Stéphane Chevaliez (S)

National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France.
INSERM U955, Créteil, France.

Leïla Saboni (L)

Department of Infectious Diseases - Santé publique France, French national public health agency, 12 rue du Val d'Osne, 94415, Saint-Maurice, Cedex, France.

Claire Sauvage (C)

Department of Infectious Diseases - Santé publique France, French national public health agency, 12 rue du Val d'Osne, 94415, Saint-Maurice, Cedex, France.

Cécile Sommen (C)

Department of Infectious Diseases - Santé publique France, French national public health agency, 12 rue du Val d'Osne, 94415, Saint-Maurice, Cedex, France.

Francis Barin (F)

National Reference Center for HIV, Inserm U1259 & University Hospital, Tours, France.

Antonio Alexandre (A)

Equipe Nationale d'Intervention en Prévention et Santé pour les Entreprises (ENIPSE), Paris, France.

Marie Jauffret-Roustide (M)

Department of Infectious Diseases - Santé publique France, French national public health agency, 12 rue du Val d'Osne, 94415, Saint-Maurice, Cedex, France.
Cermes 3, Inserm U988, UMR CNRS 8211, EHESS, Paris Descartes University, Paris, France.

Florence Lot (F)

Department of Infectious Diseases - Santé publique France, French national public health agency, 12 rue du Val d'Osne, 94415, Saint-Maurice, Cedex, France.

Annie Velter (A)

Department of Infectious Diseases - Santé publique France, French national public health agency, 12 rue du Val d'Osne, 94415, Saint-Maurice, Cedex, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH